NCT01571960View on ClinicalTrials.gov

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

January 31, 2016

Conditions
HIV Infections
Interventions
BIOLOGICAL

GEO-D03 DNA vaccine

Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid

BIOLOGICAL

MVA/HIV62B (MVA62B) vaccine

1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid

BIOLOGICAL

Placebo for GEO-D03 DNA

Administered as a 1-mL IM injection into the deltoid

BIOLOGICAL

Placebo for MVA62B:

Administered as a 1-mL IM injection into the deltoid

Trial Locations (4)

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

35294

Alabama CRS, Birmingham

94143

Bridge HIV CRS, San Francisco

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

All Listed Sponsors
collaborator

GeoVax, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01571960 - Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults | Biotech Hunter | Biotech Hunter